Combined perfusion MRI and dopamine transporter targeted PET imaging may inform future prospective clinical trials, thereby providing an improved mechanistic understanding of PD and related neurodegenerative diseases, and laying the foundation for the development of early disease biomarkers and potential therapeutic targets. Here, SLC6A3 is linked to Parkinson disease.